目的：为了研究长期功能和解剖学结果，中断模式，根据丹麦国家指南，使用雷珠单抗(PRN)方案治疗糖尿病性黄斑水肿(DME)的患者的药物转换和未改善率.
方法：回顾性队列研究，对2011年1月至2013年12月在大哥本哈根地区开始接受雷珠单抗玻璃体内治疗的566例中心参与DME患者的566只眼进行了研究。从2011年1月至2016年3月的数据库和患者记录中检索数据，并使用混合模型统计数据进行分析。
结果：在后续行动结束时，24.6%的患者在积极的雷珠单抗随访中，25.4%的人改用其他玻璃体内药物治疗，31.6%因病情稳定而停药,13.8%的人失去了随访，1.4%的人因为低视力(VA)而停产，3.2%已经死亡。在基线,平均最佳矫正视力（BCVA）和平均中央分场厚度（CST）分别为64.9（±15.0）个字母和400.2（±120.3）μm。从基线到随访3、12、24、36和48个月，BCVA的平均变化和CST的平均变化分别为3.9、3.5、2.7、1.8、2.3个字母和-97.4、-102.6、-106.9、-105.9、-131.6μm，分别。第1年的平均注射次数为6.1，第4年为1.8。在93名患者中，在BCVA或CST上，两种药物转换为阿柏西普没有差异。在79名患者中，与第一年的基线相比，CST下降<10%。
结论：在单中心临床环境中，根据丹麦国家指南，566例接受雷珠单抗治疗的DME患者随访长达4年。最佳矫正视力（BCVA）结果处于临床研究的低端，但在更广泛的人群中进行了研究，并通过更少的注射实现了目标。
OBJECTIVE: To investigate long-term functional and anatomical outcomes, discontinuation patterns, drug switching and rates of nonimprovement in patients treated with ranibizumab pro re nata (PRN) regimen for diabetic macular oedema (DME) according to the Danish national
guidelines.
METHODS: Retrospective cohort study of 566 eyes in 566 patients with centre-involved DME who started intravitreal treatment with ranibizumab between January 2011 and December 2013 in the Greater Copenhagen region. Data were retrieved from a database and patient records between January 2011 and March 2016 and analysed using mixed-model statistics.
RESULTS: At the conclusion of follow-up, 24.6% were in active ranibizumab follow-up, 25.4% had switched to other intravitreal pharmacotherapy, 31.6% had been discontinued because of disease stability, 13.8% had been lost to follow-up, 1.4% had been discontinued because of low visual acuity (VA), and 3.2% had died. At baseline, mean best-corrected visual acuity (BCVA) and mean central subfield thickness (CST) were 64.9 (±15.0) letters and 400.2 (±120.3) μm. Mean change in BCVA and mean change in CST from baseline to 3, 12, 24, 36 and 48 months of follow-up were +3.9, +3.5, +2.7, +1.8, +2.3 letters and -97.4, -102.6, -106.9, -105.9, -131.6 μm, respectively. Mean number of injections was 6.1 in year 1 and 1.8 in year 4. In 93 patients, drug switching to aflibercept showed no difference between the two drugs on BCVA or CST. In 79 patients, CST decreased <10% compared to baseline during the first year.
CONCLUSIONS: In a single-centre clinical setting, 566 patients treated for DME with ranibizumab according to the Danish national
guidelines were followed for up to 4 years. Best-corrected visual acuity (BCVA) outcomes are in the low end of clinical studies, but studied on a wider population and achieved with fewer injections.
